<div>Figure 1 – Geographical area covered by responding surgeons/MDTs</div><h2 data-label="references" class="ltx_title_subsection">References</h2><div>1. Thyroid cancer incidence statistics | Cancer Research UK.
https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/thyroid-cancer/incidence#heading-Three.
Accessed December 16, 2019.</div><div>2. Nickel B, Brito JP, Moynihan R, Barratt A, Jordan S, McCaffery K.
Patients’ experiences of diagnosis and management of papillary thyroid
microcarcinoma: A qualitative study. <i>BMC Cancer</i> . 2018;18(1):1-10.
doi:10.1186/s12885-018-4152-9</div><div>3. Sipos JA, Mazzaferri EL. Thyroid Cancer Epidemiology and Prognostic
Variables. <i>Clin Oncol</i> . 2010;22(6):395-404.
doi:10.1016/J.CLON.2010.05.004</div><div>4. Roti E, degli Uberti EC, Bondanelli M, Braverman LE. Thyroid
papillary microcarcinoma: a descriptive and meta-analysis study.<i>Eur J Endocrinol</i> . 2008;159(6):659-673. doi:10.1530/EJE-07-0896</div><div>5. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid
Association Management Guidelines for Adult Patients with Thyroid
Nodules and Differentiated Thyroid Cancer: The American Thyroid
Association Guidelines Task Force on Thyroid Nodules and Differentiated
Thyroid Cancer. <i>Thyroid</i> . 2016;26(1):1-133.
doi:10.1089/thy.2015.0020</div><div>6. Perros P, Boelaert K, Colley S, et al. British Thyoid Assoication
Guidelines for the Management of Thyroid Cancer. <i>Clin Endocrinol
(Oxf)</i> . 2014;81:1-122. doi:10.1111/cen.12515</div><div>7. Chadwick D, Kinsman R, Walton P. <i>The British Association of
Endocrine &amp; Thyroid Surgeons Fourth National Audit Report</i> .; 2012.</div><div>8. Ullmann TM, Gray KD, Stefanova D, et al. The 2015 American Thyroid
Association guidelines are associated with an increasing rate of
hemithyroidectomy for thyroid cancer. <i>Surgery</i> .
2019;166(3):349-355. doi:10.1016/j.surg.2019.03.002</div><div>9. Hirshoren N, Kaganov K, Weinberger JM, et al. Thyroidectomy practice
after implementation of the 2015 American thyroid association guidelines
on surgical options for patients with well-differentiated thyroid
carcinoma. <i>JAMA Otolaryngol - Head Neck Surg</i> .
2018;144(5):427-432. doi:10.1001/jamaoto.2018.0042</div><div>10. Haymart MR, Banerjee M, Yang D, Stewart AK, Koenig RJ, Griggs JJ.
The role of clinicians in determining radioactive iodine use for
low-risk thyroid cancer. <i>Cancer</i> . 2013;119(2):259-265.
doi:10.1002/cncr.27721</div><div>11. Haymart MR, Banerjee M, Yang D, et al. Variation in the management
of thyroid cancer. <i>J Clin Endocrinol Metab</i> . 2013;98(5):2001-2008.
doi:10.1210/jc.2012-3355</div><div>12. Haymart MR, Banerjee M, Yang D, et al. The relationship between
extent of thyroid cancer surgery and use of radioactive iodine.<i>Ann Surg</i> . 2013;258(2):354-358. doi:10.1097/SLA.0b013e31826c8915</div><div>13. Papaleontiou M, Banerjee M, Yang D, Sisson JC, Koenig RJ, Haymart
MR. Factors that influence radioactive iodine use for thyroid cancer.<i>Thyroid</i> . 2013;23(2):219-224. doi:10.1089/thy.2012.0380</div><div>14. BAETS. De-anonymised numbers 2016.
http://www.baets.org.uk/wp-content/uploads/Deanonymised-BAETS-Surgeon-Data-2016.pdf.
Published 2016.</div><div>15. Adam MA, Thomas S, Hyslop T, Scheri RP, Roman SA, Sosa JA. Exploring
the relationship between patient age and cancer- Specific survival in
papillary thyroid cancer: Rethinking current staging systems. <i>J
Clin Oncol</i> . 2016;34(36):4415-4420. doi:10.1200/JCO.2016.68.9372</div><div>16. IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated
Thyroid Cancer Patients - Full Text View - ClinicalTrials.gov.
https://clinicaltrials.gov/ct2/show/NCT01398085. Accessed July 10, 2019.</div><div>17. Adam MA, Pura J, Gu L, et al. Extent of Surgery for Papillary
Thyroid Cancer Is Not Associated With Survival. <i>Ann Surg</i> .
2014;260(4):601-607. doi:10.1097/SLA.0000000000000925</div><div>18. Haigh PI, Urbach DR, Rotstein LE. Extent of Thyroidectomy Is Not a
Major Determinant of Survival in Low- or High-Risk Papillary Thyroid
Cancer. <i>Ann Surg Oncol</i> . 2005;12(1):81-89.
doi:10.1007/s10434-004-1165-1</div><div>19. Vargas-Pinto S, Romero Arenas MA. Lobectomy Compared to Total
Thyroidectomy for Low-Risk Papillary Thyroid Cancer: A Systematic
Review. <i>J Surg Res</i> . 2019;242:244-251.
doi:10.1016/j.jss.2019.04.036</div><div>20. Harries V, Wang LY, McGill M, et al. Should multifocality be an
indication for completion thyroidectomy in papillary thyroid carcinoma?
In: <i>Surgery (United States)</i> . Mosby Inc.; 2019.
doi:10.1016/j.surg.2019.03.031</div><div>21. Geron Y, Benbassat C, Shteinshneider M, et al. Multifocality Is not
an Independent Prognostic Factor in Papillary Thyroid Cancer: A
Propensity Score-Matching Analysis. <i>Thyroid</i> . 2019;29(4):513-522.
doi:10.1089/thy.2018.0547</div><div>22. Nickel B, Semsarian C, Moynihan R, et al. Public perceptions of
changing the terminology for low-risk thyroid cancer: a qualitative
focus group study. <i>BMJ Open</i> . 2019;9(2):e025820.
doi:10.1136/bmjopen-2018-025820</div><div>23. Stacey D, Légaré F, Lewis K, et al. Decision aids for people facing
health treatment or screening decisions. <i>Cochrane Database Syst
Rev</i> . April 2017. doi:10.1002/14651858.CD001431.pub5</div><div>24. Hoffmann TC, Légaré F, Simmons MB, et al. Shared decision making:
what do clinicians need to know and why should they bother? <i>Med J
Aust</i> . 2014;201(1):35-39. doi:10.5694/mja14.00002</div>